wherea
reduct
transfus
relat
viral
transmiss
prioriti
last
decad
bacteri
infect
transmit
transfus
still
remain
associ
high
morbid
mortal
constitut
frequent
infecti
risk
transfus
problem
especi
concern
platelet
concentr
favor
bacteri
growth
condit
review
give
overview
platelet
transfusionrel
bacteri
contamin
well
differ
strategi
reduc
problem
use
either
bacteri
detect
inactiv
method
reduct
transfus
relat
viral
transmiss
hiv
hbv
hcv
prioriti
blood
transfus
servic
implement
antibodi
screen
follow
nucleic
acid
amplif
techniqu
nat
introduc
blood
donor
screen
last
decad
larg
contribut
reduct
nevertheless
blood
product
remain
threat
emerg
bloodtransmit
infect
viru
protozoan
helminth
bacteria
prion
bacteri
transfus
relat
transmiss
still
associ
high
morbid
mortal
platelet
especi
affect
risk
septic
infect
commonli
associ
platelet
transfus
favor
bacteri
growth
condit
room
temperatur
storag
allow
growth
even
small
bacteri
inoculum
ii
biolog
composit
platelet
concentr
estim
rate
bacteri
platelet
contamin
unit
wholeblood
apheresisderiv
platelet
sever
sepsi
may
associ
one
contamin
platelet
unit
transfus
risk
bacteri
contamin
platelet
concentr
estim
time
higher
combin
risk
hiv
hbv
hcv
transfus
relat
sepsi
often
recogn
real
clinic
fatal
preval
probabl
underestim
platelet
transfusionrel
bacteri
contamin
data
unit
state
bacteri
contamin
consid
transfus
error
second
common
caus
death
relat
transfus
mention
holm
et
al
estim
number
patient
receiv
bacteri
contamin
platelet
per
year
rang
result
case
clinic
sepsi
estim
fatal
death
risk
usa
estim
platelet
concentr
english
hemovigil
system
report
transfusionrel
bacteri
contamin
lead
death
attribut
platelet
contamin
franc
fournierwirth
et
al
report
incid
transfus
relat
reaction
due
bacteri
contamin
platelet
unit
associ
sever
morbid
even
mortal
case
year
period
death
rate
estim
one
death
per
distribut
platelet
concentr
sever
mechan
may
lead
platelet
contamin
major
contamin
skin
flora
site
punction
pathogen
essenti
gram
posit
bacteria
like
staphylococcu
aureu
coagulas
neg
staphylococci
viridan
group
streptococci
bacillu
spp
corynebacteria
well
anaerob
diphteroid
gram
posit
bacilli
propionibacterium
acn
review
deal
transfusiontransmit
bacteri
infect
wagner
report
bacteria
detect
platelet
unit
implic
clinic
situat
transfus
associ
sepsi
aerob
gramposit
bacteria
howev
presenc
gram
neg
organ
outcom
frequent
fatal
compar
gram
posit
one
distribut
bacteria
found
case
transfus
relat
sepsi
show
staphylococcu
spp
case
escherichia
coli
bacillu
spp
salmonella
spp
streptococcu
spp
serratia
spp
enterobact
spp
organ
clinician
awar
uncommon
pathogen
might
encount
platelet
prepar
infrequ
donor
bacteremia
may
present
blood
collect
also
lead
platelet
contamin
larg
studi
evalu
risk
septic
platelet
transfus
reaction
septic
transfus
reaction
observ
reaction
attribut
skin
flora
contamin
result
bacteria
like
associ
transient
donor
bacteremia
furthermor
author
also
show
pool
platelet
concentr
buffi
coat
higher
bacteri
contamin
rate
compar
apheresi
platelet
total
pooledplatelet
concentr
singledonor
platelet
concentr
transfus
rate
septic
transfus
reaction
respect
thu
observ
fold
increas
rate
pooleddonor
platelet
aabb
educ
session
transfus
medicin
hillyer
et
al
report
preval
bacteri
contamin
whole
blood
deriv
platelet
per
unit
compar
apheresi
platelet
whose
preval
per
unit
effect
bacteri
screen
apheresi
platelet
evalu
eder
et
al
point
septic
reaction
associ
platelet
transfus
estim
occur
transfus
rate
contamin
platelet
determin
implement
detect
techniqu
author
hypothes
lowlevel
contamin
necessarili
associ
clear
clinic
respons
particularli
neutropen
febril
patient
often
antibiot
therapi
may
chang
clinic
pictur
occurr
sever
bacteri
infect
relat
platelet
transfus
correl
bacteri
prolifer
platelet
concentr
bacteri
contamin
cfuml
consid
seriou
infecti
risk
yomtovian
et
al
report
data
surveil
program
detect
bacteri
contamin
platelet
univers
hospit
data
concern
passiv
surveil
transfus
reactiontrigg
activ
surveil
prospect
method
surveil
period
platelet
unit
transfus
one
type
bacteri
contamin
detect
passiv
surveil
method
pseudomona
aeruginosa
old
randomdonor
platelet
thirtyeight
contamin
platelet
unit
pool
detect
activ
surveil
six
transfus
transfus
contamin
isol
blood
cultur
obtain
recipi
case
coagulaseneg
staphylococci
frequent
isol
bacteria
speci
follow
staphyloccocu
aureu
thirteen
patient
receiv
contamin
platelet
detect
activ
surveil
one
detect
passiv
surveil
develop
transfus
reaction
transfus
reaction
rate
significantli
higher
pool
randomdonor
platelet
sever
transfus
reaction
occur
case
patient
die
complic
like
associ
transfus
contamin
platelet
unit
pseudomona
aeruginosa
staphylococcu
aureu
serratia
marcescen
nine
transfusionreact
associ
bacteri
count
cfuml
virul
bacteria
appear
import
bacteri
load
howev
transfus
reaction
fever
rigor
hypotens
observ
coagulaseneg
staphylococci
bacteri
count
low
cfuml
bacteri
growth
increas
time
platelet
unit
older
risk
high
bacteri
amount
higher
consequ
higher
risk
sepsi
fda
allow
extens
platelet
storag
five
seven
day
decis
led
increas
rate
platelet
transfusionrel
infect
directli
associ
oldest
transfus
unit
therefor
storag
reduc
seven
five
day
mention
sever
clinic
manifest
relat
contamin
platelet
unit
determin
quantit
qualit
paramet
number
cfu
infus
type
bacteria
rate
prolifer
latenc
phase
wherea
case
fever
chill
present
transfus
mani
case
patient
remain
asymptomat
symptomat
recipi
fever
chill
may
observ
within
two
hour
start
transfus
hypotens
nausea
vomit
diarrhea
oliguria
respiratori
symptom
shock
may
observ
sever
septic
transfus
reaction
also
depend
patient
characterist
may
sever
immunocompromis
patient
order
reduc
risk
posttransfus
sepsi
bacteri
contamin
platelet
variou
procedur
implement
improv
donor
select
singledonor
apheresi
platelet
reduct
contamin
risk
phlebotomi
process
optim
skin
disinfect
procedur
remov
first
ml
initi
collect
blood
storag
time
limit
bacteri
detect
inactiv
method
inde
major
caus
platelet
contamin
normal
skin
flora
site
punction
optim
skin
disinfect
may
significantli
reduc
contamin
howev
collect
needl
enter
skin
bacteria
may
introduc
blood
differ
studi
suggest
remov
first
aliquot
initi
collect
blood
may
reduc
risk
bacteri
contamin
blood
donat
method
detect
bacteri
contamin
platelet
cultur
method
compar
bacteri
detect
method
surrog
test
ph
measur
glucos
level
determin
gram
stain
color
shown
low
sensit
thu
recommend
two
method
approv
fda
detect
bacteri
contamin
platelet
first
one
bactalert
inc
autom
colorimetr
blood
cultur
method
base
detect
carbon
dioxid
produc
prolifer
microorgan
allow
detect
aerob
anaerob
bacteria
well
yeast
fungu
second
one
ebd
pall
corpor
enhanc
bacteri
detect
method
base
measur
oxygen
consumpt
bacteria
milieu
comparison
advantag
disadvantag
method
present
tabl
adapt
verax
biomed
platelet
pgd
test
bacteri
detect
verax
biomed
inc
new
rapid
qualit
immunoassay
test
detect
aerob
anaerob
bacteria
leukocyt
reduc
apheresi
platelet
howev
absenc
suffici
data
comparison
method
bactalert
pall
ebd
possibl
bactalert
autom
colorimetr
blood
cultur
method
allow
detect
aerob
anaerob
bacteria
well
yeast
fungal
microorgan
two
cultur
bottl
one
aerob
one
anaerob
pathogen
bottom
bottl
contain
ph
sensit
liquid
sensor
chang
color
accord
amount
co
releas
wherea
bacteria
produc
co
yeast
fungi
high
acidproduc
organ
inocul
approxim
ml
platelet
sampl
necessari
bottl
perform
hour
collect
bottl
incub
co
product
correl
alter
reflect
light
sensor
color
chang
alarm
set
bottl
continu
analyz
test
day
system
use
routin
detect
platelet
bacteri
contamin
netherland
belgium
wale
sever
year
mcdonald
et
al
report
data
result
evalu
bactalert
system
inocul
old
apheresi
platelet
differ
bacteri
speci
gram
posit
gram
neg
one
fungal
microorgan
concentr
cfuml
result
compar
thioglycol
broth
cultur
mean
time
bacteri
detect
rang
hour
except
propionibacterium
acn
hour
analog
result
obtain
brecher
et
al
also
confirm
larg
delay
requir
detect
propionibacterium
acn
howev
import
note
anaerob
propionibacterium
acn
poor
growth
aerob
platelet
condit
clinic
relev
clear
bacteri
load
may
low
freshli
collect
platelet
cfuml
sometim
even
cfuml
storag
period
hour
requir
inocul
order
allow
bacteri
growth
avoid
fals
neg
result
better
assess
preval
natur
bacteri
contamin
pool
apheresi
platelet
germ
german
evalu
regular
monitor
studi
group
red
cross
transfus
servic
initi
prospect
multimemb
studi
includ
differ
center
result
studi
report
schrezenmei
et
al
bactalert
method
use
analyz
platelet
concentr
collect
apheresi
pool
platelet
platelet
concentr
first
posit
cultur
bacteria
identifi
among
concentr
confirm
posit
second
cultur
signific
differ
rate
confirm
posit
platelet
concentr
apheresi
pool
platelet
among
confirm
posit
platelet
concentr
bacteria
isol
skin
flora
bacteria
propionibacterium
acn
found
staphylococci
speci
staphylococcu
epidermidi
case
serratia
marcescen
staphylococcu
aureu
potenti
pathogen
bacteria
isol
respect
one
plasma
pool
platelet
concentr
one
apheresi
platelet
concentr
studi
demonstr
larg
scale
routin
screen
platelet
prepar
differ
blood
center
feasibl
howev
author
observ
screen
allow
prevent
transfus
contamin
unit
interv
time
need
inocul
detect
contamin
addit
risk
fals
neg
result
elimin
approach
two
case
lifethreaten
sepsi
due
bacillu
cereu
contamin
despit
bactalert
detect
method
describ
te
boekhorst
et
al
netherland
anoth
import
multicent
german
studi
compar
three
bacteri
detect
method
routin
condit
schmidt
et
al
report
sever
transfus
reaction
transfus
split
apheresi
platelet
concentr
contamin
klebsiella
pneumonia
despit
neg
screen
bactalert
pall
ebd
detect
method
netherland
te
boekhorst
et
al
report
experi
bactalert
system
implement
center
routin
bacteri
screen
platelet
octob
period
two
year
pool
platelet
screen
detect
contamin
alreadi
releas
time
detect
nineti
percent
alreadi
transfus
advers
reaction
fever
hypotens
unexplain
clinic
deterior
observ
contamin
transfus
earli
detect
hour
bacteri
contamin
microbiolog
confirm
possibl
concentr
could
recal
late
detect
hour
contamin
concentr
could
recal
author
also
observ
bactalert
screen
cultur
becam
posit
incub
hour
note
low
rate
contrast
sever
studi
show
higher
rate
bacteri
detect
incub
hour
instanc
wagner
robinett
show
deliber
bacteri
inocul
platelet
concentr
could
detect
hour
case
brecher
et
al
report
detect
inocul
microorgan
apheresi
platelet
unit
except
propionibacterium
acn
mean
time
hour
cfuml
hour
cfuml
te
boekhorst
et
al
point
fact
differ
could
explain
presum
low
bacteri
load
platelet
concentr
compar
experiment
inocul
load
previous
mention
pall
ebd
cultur
method
system
base
bacteri
consumpt
oxygen
allow
detect
aerob
facult
anaerob
bacteria
twentyfour
hour
collect
ml
platelet
concentr
filter
order
remov
platelet
leukocyt
inocul
sampl
bag
pouch
contain
two
tablet
sodium
polyanethol
sulphon
dissolv
tablet
reduc
natur
inhibitor
bacteri
growth
also
act
platelet
aggreg
agent
order
lower
platelet
competit
consumpt
ii
trypticas
soy
mediumcontain
tablet
enhanc
sensit
provid
nutrient
bacteri
growth
sampl
incub
hour
level
measur
like
bactalert
pall
ebd
vitro
sensit
determin
cfuml
moreov
order
reduc
risk
fals
neg
result
period
storag
hour
advoc
perform
pall
ebd
evalu
four
test
site
inocul
cfuml
differ
bacteri
speci
known
associ
fatal
platelet
transfus
relat
outcom
inocul
sampl
transfer
pall
ebd
bag
immedi
inocul
hour
storag
result
report
holm
et
al
show
sampl
incub
hour
inocul
detect
contamin
sensit
fals
posit
obtain
uninocul
platelet
fournierwirth
et
al
report
result
studi
perform
transfus
center
franc
pool
apheresi
platelet
aim
studi
evalu
abil
pall
ebd
system
detect
bacteri
contamin
reduct
incub
time
result
compar
bactalert
system
consid
studi
refer
low
level
cfuml
differ
strain
bacteria
inocul
platelet
unit
platelet
store
hour
articl
tabl
comparison
advantag
disadvantag
bactalert
pall
ebd
accord
data
report
schmidt
et
al
sensit
effici
manag
bactalert
pall
ebd
compar
multicenterstudi
carri
german
center
concern
pool
platelet
apheresi
sensit
sensit
good
specif
detect
aerob
anaerob
bacteria
yeast
fungal
microorgan
close
system
bottl
continu
analyz
test
day
easi
quick
handl
easi
quick
handl
disadvantag
detect
aerob
facult
specif
anaerob
bacteria
punctual
measur
time
wherea
platelet
open
system
may
transfus
day
collect
platelet
may
releas
time
detect
evalu
reveal
better
sensit
bactalert
system
identifi
posit
sampl
miss
pall
ebd
specif
bactalert
test
sampl
significantli
lower
compar
pall
ebd
test
sampl
sampl
time
detect
rang
hour
sixtythre
contamin
bag
incub
hour
sixtyon
detect
posit
hour
hour
level
sampl
neg
hour
contamin
bacillu
cereu
near
detect
threshold
howev
neg
sampl
detect
level
fals
posit
result
specif
conclud
pall
ebd
method
allow
test
platelet
concentr
hour
collect
similarli
bact
alert
system
limit
pall
ebd
detect
system
concern
failur
detect
anaerob
bacteria
howev
anaerob
organ
rare
associ
fatal
infect
platelet
transfus
sensit
effici
manag
bactalert
pall
ebd
compar
multicent
studi
carri
german
center
concern
pool
platelet
apheresi
platelet
microbiolog
refer
laboratori
evalu
initi
posit
result
evalu
reveal
better
sensit
bactalert
system
identifi
posit
sampl
miss
pall
ebd
howev
enhanc
sensit
bactalert
system
offset
reduc
specif
defin
studi
number
falseposit
test
sampl
specif
bactalert
test
sampl
significantli
lower
compar
pall
ebd
test
sampl
howev
author
conclud
reduc
specif
might
accept
bactalert
detect
posit
sampl
microbiolog
confirm
pall
ebd
detect
one
posit
sampl
sampl
consid
initi
posit
howev
initi
posit
result
confirm
analysi
second
sampl
either
satellit
bag
origin
platelet
bag
relat
erythrocyt
bag
case
pool
platelet
possibl
explan
may
exogen
contamin
test
procedur
reason
pall
ebd
close
system
may
prefer
bactalert
open
one
order
provid
rapid
sensit
highli
specif
result
molecular
technolog
base
detect
ribosom
rna
wide
varieti
bacteria
platelet
contamin
sampl
contain
cfuml
also
evalu
chaney
et
al
describ
new
process
allow
target
bacteri
ribosom
rna
five
step
cell
lyse
lead
releas
ribosom
rna
ii
hybrid
bacteri
ribosom
rna
biotin
rutheniumlabel
oligonucleotid
probe
pair
iii
captur
label
ribosom
rna
streptavidinco
magnet
bead
iv
set
rna
electrod
surfac
detect
rutheniumlabel
ribosom
rna
applic
voltag
v
follow
gener
electrochemiluminesc
signal
approach
author
abl
obtain
linear
relationship
electrochemiluminesc
signal
repres
ribosom
rna
level
number
cfuml
howev
even
method
appear
suitabl
routin
applic
sensit
suffici
allow
detect
approxim
cfuml
et
al
recent
publish
result
studi
evalu
bacteri
spread
differ
blood
compon
infect
inocul
klebsiella
pneumonia
staphylococcu
epidermidi
use
rtpcr
klebsiella
pneumonia
detect
platelet
concentr
immedi
prepar
staphylococcu
epidermidi
slower
growth
detect
hour
whole
separ
process
author
conclud
hour
storag
necessari
process
rtpcr
even
molecular
base
technolog
repres
high
potenti
bacteri
detect
applic
context
detect
bacteria
platelet
concentr
yet
demonstr
furthermor
use
limit
cost
complex
use
critic
avail
bacterialderiv
nucleic
acid
amplif
reagent
review
literatur
publish
improv
bacteriolog
safeti
platelet
transfus
blajchman
et
al
point
bacteri
contamin
current
detect
molecular
method
clear
bacteri
dna
rrna
appropri
test
marker
one
import
practic
problem
use
broadrang
pcr
contamin
assay
exogen
bacteri
dna
nucleotid
amplif
reagent
particularli
bacteri
deriv
enzym
bacteri
dna
sequenc
commonli
found
human
blood
moreov
detect
minor
amount
bacteri
dna
among
high
quantiti
human
dna
may
also
constitut
problem
knowledg
method
base
bacteri
amplif
techniqu
current
employ
routin
screen
platelet
concentr
pathogen
reduct
technolog
allow
inactiv
virus
bacteria
contamin
platelet
concentr
two
main
differ
approach
describ
intercept
blood
system
ceru
corpor
use
amotosalen
synthet
psoralen
organ
compound
found
fruit
veget
like
lime
celeri
amotosalen
compound
potenti
penetr
cell
cross
nuclear
membran
revers
intercal
helic
region
nucleic
acid
exposur
longwavelength
ultraviolet
light
uva
nm
lead
coval
crosslink
amotosalen
molecul
pyrimidin
base
block
dna
rna
replic
cell
pathogen
nucleic
acid
genom
light
treatment
residu
amotosalen
well
metabolit
remov
compound
adsorb
devic
prolong
incub
platelet
nuclei
affect
psoralen
lin
et
al
report
result
advoc
effici
approach
viru
inactiv
author
studi
differ
famili
virus
includ
relev
blood
transfus
like
hbv
cmv
ii
virus
emerg
interest
like
parvoviru
west
nile
viru
sever
acut
respiratori
syndromehuman
coronaviru
vaccinia
viru
iii
model
virus
like
duck
hepat
viru
hbv
model
bovin
viral
diarrhea
viru
hcv
model
bluetongu
viru
felin
conjunct
viru
simian
adenoviru
porcin
parvoviru
accord
fda
process
defin
effect
pathogen
load
reduc
log
result
studi
show
signific
log
reduct
envelop
virus
uniformli
sensit
inactiv
nonenvelop
virus
show
variabl
sensit
inactiv
parvoviru
human
adenoviru
inactiv
limit
detect
wherea
nonenvelop
virus
resist
inactiv
singh
et
al
report
photochem
treatment
plasma
amotosalen
inactiv
high
level
gram
posit
streptococcu
epidermidi
gram
neg
klebisella
pneumonia
yersinia
enterocolitica
bacteria
determin
mean
log
reduct
achiev
streptococcu
epidermidi
yersinia
enterocolitica
klebisella
pneumonia
photochem
treatment
also
effici
high
initi
titer
spirochet
meanreduct
treponema
pallidum
borrelia
burgdorferi
protozoa
meanreduc
hematolog
review
tion
plasmodium
falciparum
trypanosomia
cruzi
bancrofti
microti
also
show
mainten
clot
time
plasma
coagul
factor
activ
photochem
treatment
genom
dna
leukocyt
modifi
psoralen
abl
inactiv
log
lymphocyt
disrupt
base
pair
gammairradi
grass
et
al
report
dose
amotosalen
fold
lower
dose
use
virus
bacteria
inactiv
suffici
inactiv
lymphocyt
jcm
uva
illumin
extrem
sensit
lymphocyt
psoralen
suggest
treatment
potenti
reduc
incid
leukocyt
mediat
advers
immun
reaction
associ
platelet
transfus
like
transfus
associ
graftversushost
diseas
platelet
relat
febril
nonhemolyt
transfus
reaction
platelet
concentr
treat
psoralen
seem
compar
vitro
function
compar
nontreat
platelet
concentr
viabil
seem
conserv
mccullough
et
al
report
result
sprint
trial
prospect
random
control
doubleblind
parallel
group
phase
iii
studi
carri
evalu
efficaci
safeti
photochem
treat
amotosalen
platelet
compar
nontreat
control
platelet
collect
apheresi
efficaci
defin
prevent
treatment
signific
bleed
proport
patient
grade
bleed
primari
efficaci
end
point
proport
grade
bleed
number
day
grade
bleed
one
hour
hour
platelet
count
increment
correct
count
increment
number
day
next
platelet
transfus
number
platelet
transfus
incid
platelet
refractori
number
erythrocyt
concentr
transfus
secondari
efficaci
end
point
safeti
end
point
defin
number
platelet
transfus
reaction
develop
antibodi
potenti
amotosalen
neoantigen
overal
safeti
studi
includ
thrombocytopen
patient
need
platelet
transfus
support
receiv
photochem
treat
platelet
control
platelet
requir
platelet
transfus
trial
show
wherea
hemostat
effect
photochem
treat
control
platelet
compar
transfus
treat
platelet
associ
lower
platelet
count
increment
transfus
lower
platelet
count
increment
could
partli
explain
lower
mean
platelet
dose
photochem
treat
group
vs
control
group
p
greater
proport
treat
platelet
contain
platelet
thu
patient
receiv
photochem
treat
platelet
receiv
platelet
transfus
shorter
interv
transfus
patient
receiv
convent
platelet
studi
perform
anim
human
report
evid
toxic
psoralen
treatment
webert
et
al
relat
acut
toxic
amotosalen
uva
activ
rat
lethal
threshold
dose
mgkg
dog
central
nervou
system
alter
observ
threshold
dose
mgkg
dose
respect
fold
higher
dose
use
pathogen
inactiv
reproduct
toxic
determin
histolog
rather
function
evalu
observ
threshold
mgkg
time
higher
dose
use
pathogen
inactiv
moreov
substanc
use
pathogen
inactiv
water
solubl
rapidli
excret
avoid
bioaccumul
trace
amount
treat
blood
product
addit
transfus
platelet
plasma
treat
method
appear
induc
advers
immunolog
respons
evalu
search
presenc
neoantigen
lin
et
al
evalu
potenti
photochem
treatment
amotosalen
creat
neoantigen
quantifi
amount
residu
amotosalen
photoproduct
photochem
treat
platelet
plasma
patient
serum
sampl
phase
iii
clinic
trial
includ
patient
receiv
unit
treat
platelet
plasma
assay
enzym
link
immunsorb
assay
elisa
antibodi
amotosalen
neoantigen
result
indic
neonatigen
detect
elisa
photochem
treatment
amotosalen
mirasol
prt
navig
biotechnolog
inc
system
similar
psoralenbas
method
use
differ
photosensit
riboflavin
vitamin
instead
psoralen
riboflavin
natur
compon
found
food
milk
beer
egg
yeast
leafi
veget
classifi
generallyregardedassaf
compound
fda
riboflavin
interact
nucleic
acid
exposur
uv
light
nm
caus
irrevers
damag
dnarna
direct
electron
transfer
product
singlet
oxygen
product
hydrogen
peroxid
lead
format
hydroxyl
radic
compound
adsorb
devic
remov
process
residu
riboflavin
metabolit
may
necessari
perezpujol
et
al
studi
impact
method
function
biochem
characterist
platelet
concentr
observ
flow
cytometri
studi
chang
treat
nontreat
platelet
without
modif
fvw
fibrinogen
fva
level
five
day
storag
also
show
treat
platelet
adhes
cohes
function
similar
nontreat
platelet
ruan
et
al
shown
mirasol
prt
system
abl
inactiv
virus
bacteria
platelet
concentr
observ
signific
log
reduct
cellassoci
cellfre
hiv
west
nile
viru
porcin
parvoviru
gram
posit
gram
neg
bacteria
staphylococcu
epidermidi
escherichia
coli
author
note
platelet
ph
lactat
product
rate
suggest
literatur
data
predict
recoveri
therefor
use
platelet
ph
lactat
product
rate
platelet
qualiti
indic
conclud
platelet
cell
qualiti
maintain
treatment
storag
goodrich
et
al
review
mirasol
prt
perform
confirm
system
abl
inactiv
virus
variou
bacteria
speci
staphylococcu
epidermidi
staphylococcu
aureu
escherichia
coli
pseudomona
aeruginosa
bacillu
cereu
serratia
marcescen
data
suggest
signific
reduct
risk
platelet
relat
bacteria
transmiss
kumar
et
al
show
increas
genom
dna
degrad
leukocyt
bacteria
riboflavin
uv
light
treatment
also
suggest
mirasol
prt
technolog
may
altern
gamma
irradi
prevent
transfus
associ
graftversushost
diseas
decemb
klein
et
al
report
consensu
confer
pathogen
inactiv
toronto
march
pathogen
inactiv
method
implement
soon
feasibl
safe
method
inactiv
broad
spectrum
infecti
agent
avail
author
establish
list
exist
criteria
procedur
chang
case
implement
pathogen
inactiv
suppress
screen
test
treponema
pallidum
ii
agent
low
infecti
titer
destroy
earli
pathogen
inactiv
like
west
nile
viru
actual
systemat
test
us
canada
iii
agent
sensit
pathogen
inactiv
redund
safeti
measur
taken
cmv
htlv
hbsag
method
detect
avail
nowaday
lack
specif
sensit
like
use
detect
bacteria
moreov
gamma
irradi
blood
compon
perform
elimin
risk
transfus
associ
graftversushost
diseas
could
elimin
author
conclud
agent
known
adequ
inactiv
technolog
requir
screen
test
unless
unusu
high
infecti
titer
abil
pathogen
reduct
technolog
inactiv
broad
spectrum
organ
viru
fungu
bacteria
parasit
one
conveni
answer
face
rapidli
evolv
epidemiolog
environ
well
continu
appear
new
pathogen
multipl
differ
factor
effect
contribut
occurr
emerg
reemerg
infecti
agent
migrat
travel
conflict
climat
chang
demographi
numer
less
trivial
factor
like
instanc
pet
trade
ebusi
occurr
pathogen
strong
epidem
potenti
andor
high
preval
well
divers
exist
pathogen
systemat
detect
use
standard
screen
approach
strongli
argu
introduct
inactiv
procedur
rather
continu
introduc
new
biolog
test
character
sensit
specif
bacteri
transmiss
still
constitut
signific
problem
transfus
medicin
favor
bacteri
growth
condit
storag
room
temperatur
biolog
composit
platelet
special
concern
shown
review
data
avail
suggest
bacteri
detect
technolog
avail
nowaday
may
present
fals
sens
secur
knowledg
recent
approv
revolutionari
bacteri
detect
technolog
dramat
definit
make
platelet
transfus
safe
contrast
pathogen
inactiv
demonstr
effici
howev
longterm
studi
still
need
demonstr
safeti
approach
newer
pathogen
inactiv
technolog
current
develop
like
cryofacet
red
blood
cell
platelet
technolog
use
counterflow
elutri
remov
infecti
agent
plasma
follow
ozon
treatment
germicidal
uv
releas
approach
glycoengin
platelet
order
allow
cold
storag
rapid
bacteri
detect
moment
releas
develop
summari
review
describ
recent
technolog
may
use
make
platelet
transfus
safe
particular
emphasi
prevent
bacteri
contamin
base
literatur
review
particularli
peopl
directli
involv
develop
andor
implement
particular
technolog
like
